Ferry J J, Cetnarowski A B, Sedman A J, Thomas R W, Horvath A M
Warner-Lambert/Parke-Davis, Pharmacokinetics-Drug Metabolism Department, Ann Arbor, Michigan.
J Clin Pharmacol. 1988 Jan;28(1):48-51. doi: 10.1002/j.1552-4604.1988.tb03100.x.
The potential effect of cimetidine on the pharmacokinetic profiles of quinapril and its active metabolite CI-928 was evaluated in eight healthy volunteers. Each subject received a single 40-mg quinapril dose on days 1 and 12 and cimetidine 300 mg four times daily on days 8 through 13. Serial blood and urine samples were collected for assay of quinapril and CI-928 concentrations. No statistically significant differences were observed in quinapril or CI-928 Cmax, tmax, AUC(0-infinity), beta, or percent of dose excreted in urine values for quinapril administered alone and in combination with cimetidine. Therefore, multiple-dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite, CI-928, in healthy volunteers.
在8名健康志愿者中评估了西咪替丁对喹那普利及其活性代谢物CI-928药代动力学特征的潜在影响。每位受试者在第1天和第12天接受单次40mg喹那普利剂量,在第8天至第13天每天4次接受300mg西咪替丁。采集系列血液和尿液样本以测定喹那普利和CI-928浓度。单独给予喹那普利以及与西咪替丁合用时,喹那普利或CI-928的Cmax、tmax、AUC(0-∞)、β或喹那普利尿中排泄剂量百分比的值均未观察到统计学上的显著差异。因此,多次给予西咪替丁不影响健康志愿者中喹那普利及其活性代谢物CI-928的单剂量药代动力学。